Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07603596Phase 1Not yet recruiting
Phase 1, randomised, single-blind trial of dexmedetomidine, esketamine and esmolol in postoperative delirium (POD) (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Incidence of postoperative delirium at 7 days. Planned start May 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07603596.